Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Clinical & Surgical Translation of Adult Stem Cells

Chris Duma's Biography



Chris Duma, Brain Surgeon Specialist, Hoag Neurosciences Institute

Christopher Duma, MD, FACS is a Board certified neurosurgeon specialist in surgical brain tumor management, Gamma Knife and Cyberknife radiosurgery, and the surgical treatment of movement disorders like Parkinson’s disease. He is also the first neurosurgeon in the US to implant stem cells into the human brain for Alzheimer’s disease, Parkinson’s disease and ALS. He serves as Medical Director of the Brain Tumor Program at Hoag Memorial Hospital Presbyterian Hospital in Newport Beach, CA, where he has perfected techniques for both open, general brain surgery and Gamma Knife radiosurgery. With nearly 27 years of neurosurgery experience to his credit, Dr. Duma is uniquely qualified to offer an unbiased and very modern opinion on how any brain pathology should be managed. Dr. Duma is a Diplomate of the American Board of Neurological Surgery, and a Fellow of the American College of Surgeons. He received his general neurosurgical training at Georgetown University Hospital in Washington, DC, followed by a fellowship at the University of Pittsburgh, Presbyterian Hospital in Gamma Knife Radiosurgery and Stereotactic and Functional Neurosurgery. He has been involved in medical research since his undergraduate years, beginning at Cornell University School of Medicine’s Department of Neuropharmacology and his graduate years at Memorial-Sloan Kettering Cancer Center’s Department of Neurology Pain Service.

Chris Duma Image

The First United States Experience with Autologous Intraventricular SVF for Neurodegenerative Disorders: First Year Results of a Phase 1 trial in 18 Patients

Monday, 9 November 2015 at 15:40

Add to Calendar ▼2015-11-09 15:40:002015-11-09 16:40:00Europe/LondonThe First United States Experience with Autologous Intraventricular SVF for Neurodegenerative Disorders: First Year Results of a Phase 1 trial in 18 PatientsClinical and Surgical Translation of Adult Stem Cells in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com

Prior to this work, there has been no experience in the United States injecting autologous SVF directly into the human brain. Potential risks and benefits have been unknown. We present our first year results in 18 patients treated with intraventricular  SVF.

While double-blind studies are the hallmark of true scientific proof, empirical data should not be ignored as it sets up the basis for further studies.  Our patients had no complications from injection, and a phase 3 study for efficacy is pending. The best results were seen in AD and MS, and in patients with multiple injections.


Add to Calendar ▼2015-11-09 00:00:002015-11-10 00:00:00Europe/LondonClinical and Surgical Translation of Adult Stem CellsClinical and Surgical Translation of Adult Stem Cells in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com